- Trials with a EudraCT protocol (118)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
118 result(s) found for: Thyroid stimulating hormone.
Displaying page 2 of 6.
EudraCT Number: 2020-001218-39 | Sponsor Protocol Number: svenne0405 | Start Date*: 2020-11-17 | |||||||||||
Sponsor Name:fertility clinic, Herlev university hospital | |||||||||||||
Full Title: Estradiol levels in early pregnancy after natural, estradiol + progesterone or gonadotrophin stimulated frozen embryo transfer (FET) cycle | |||||||||||||
Medical condition: Infertile women | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004409-34 | Sponsor Protocol Number: ESN364-PCO-201 | Start Date*: 2015-01-21 | |||||||||||
Sponsor Name:Ogeda S.A | |||||||||||||
Full Title: Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Po... | |||||||||||||
Medical condition: Polycystic Ovarian Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017245-64 | Sponsor Protocol Number: OG09/9146 | Start Date*: 2010-09-07 |
Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
Full Title: The effect of metformin co-treatment in hormone-replacement frozen embryo replacement cycles in women with polycystic ovary syndrome. | ||
Medical condition: Polycystic Ovary Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2009-017674-20 | Sponsor Protocol Number: XM17-05 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:BioGeneriX AG | |||||||||||||
Full Title: Efficacy, safety and tolerability of XM17 compared to Gonal-f® in women undergoing assisted reproductive technologies. A multi-national, multi-centre, randomised, controlled, assessor-blind, parall... | |||||||||||||
Medical condition: infertile but ovulatory women undergoing superovulation for assisted reproduction technologies | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) CZ (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002193-63 | Sponsor Protocol Number: C-700-03 | Start Date*: 2021-09-17 | |||||||||||
Sponsor Name:Agenus, Inc. | |||||||||||||
Full Title: A Phase 3 Trial of Balstilimab versus Investigator Choice Chemotherapy in Patients with Recurrent Cervical Cancer after Platinum-Based Chemotherapy | |||||||||||||
Medical condition: recurrent, persistent, or metastatic cervical cancer that have progressed after receiving platinum-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002379-40 | Sponsor Protocol Number: CAFQ056B2278 | Start Date*: 2012-01-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004495-36 | Sponsor Protocol Number: M90-516 | Start Date*: 2014-11-28 | |||||||||||
Sponsor Name:Abbvie previously known as Abbott | |||||||||||||
Full Title: Study of Lupron Depot in the Treatment of Central Precocious Puberty | |||||||||||||
Medical condition: Central Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000524-14 | Sponsor Protocol Number: MTF-C-019 | Start Date*: 2006-06-22 |
Sponsor Name:ViraNative AB | ||
Full Title: Comparison of virological response during high and low-dose regimen with natural IFN α in combination with ribavirin in patients with genotype 1 chronic hepatitis C who have experienced an incomple... | ||
Medical condition: Chronic hepatitis C, genotype 1 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002260-31 | Sponsor Protocol Number: GINECO-OV243b | Start Date*: 2020-10-01 | |||||||||||||||||||||
Sponsor Name:ARCAGY-GINECO | |||||||||||||||||||||||
Full Title: Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line advanced small cell ovarian carcinoma of hypercalcemic type | |||||||||||||||||||||||
Medical condition: Advanced small cell ovarian carcinoma of hypercalcemic type | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010952-81 | Sponsor Protocol Number: OG08/8802 | Start Date*: 2009-08-17 |
Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
Full Title: The use of Metformin and Gonadotrophin Releasing Hormone Antagonist for the treatment of women with Polycystic Ovary Syndrome undergoing In-vitro Fertilisation-Embryo Transfer. | ||
Medical condition: Polycystic ovary syndrome. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-004815-33 | Sponsor Protocol Number: TransCon_PTH_TCP-201 | Start Date*: 2019-09-27 | |||||||||||
Sponsor Name:Ascendis Pharma Bone Diseases A/S | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administ... | |||||||||||||
Medical condition: Hypoparathyroidism (HP) in Adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002952-34 | Sponsor Protocol Number: NN9924-4437 | Start Date*: 2020-09-07 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) BE (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004413-33 | Sponsor Protocol Number: KBT-004 | Start Date*: 2007-10-26 | |||||||||||
Sponsor Name:Karo Bio AB | |||||||||||||
Full Title: A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB 2115 as add on to Statin Treatment in Patients With Dyslipid... | |||||||||||||
Medical condition: Primary hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001485-15 | Sponsor Protocol Number: MYR204 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:Gilead Sciences Inc. | |||||||||||||
Full Title: A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta | |||||||||||||
Medical condition: Chronic Hepatitis Delta | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002993-29 | Sponsor Protocol Number: M13-625 | Start Date*: 2015-07-15 | |||||||||||
Sponsor Name:Abbott Laboratories GmbH | |||||||||||||
Full Title: A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Crinone 8% intravaginal progesterone gel 90 mg daily ... | |||||||||||||
Medical condition: Treatment for the luteal support in in-vitro fertilization (IVF). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001295-36 | Sponsor Protocol Number: SRM105106 | Start Date*: 2007-08-22 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 ad... | ||
Medical condition: Treatment of moderate to extremely severe vasomotor symptoms in healthy postmenopausal women | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002215-26 | Sponsor Protocol Number: M13-563 | Start Date*: 2013-07-18 | |||||||||||
Sponsor Name:Abbott Laboratories GmbH | |||||||||||||
Full Title: A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Intravaginal Micronized Progesterone C... | |||||||||||||
Medical condition: Female infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) ES (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001055-50 | Sponsor Protocol Number: EP-001 | Start Date*: 2016-08-08 |
Sponsor Name:Empros Pharma AB | ||
Full Title: A, single center, controlled, multiple dose, randomized study during two weeks, investigating the effect of the test formulation on efficacy, safety and markers for appetite regulation, glucose and... | ||
Medical condition: Obesity and diabetes, type 2. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002602-78 | Sponsor Protocol Number: DSG-HSP-201 | Start Date*: 2011-09-21 | |||||||||||
Sponsor Name:Teva Women's Health Research&Development, a division of Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women | |||||||||||||
Medical condition: The impact of an experimental birth control drug on hemostatic parameters (characteristics of the blood) compared to a standard marketed birth control pill in healthy women (contraceptive) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004670-24 | Sponsor Protocol Number: SYR-322-PLC-010 | Start Date*: 2006-05-26 |
Sponsor Name:Takeda Global Research & Development Center, Inc. | ||
Full Title: A multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and safety of SYR110322 (SYR-322) Compared with Placebo in Subjects with Type 2 Diabetes | ||
Medical condition: Type II diabetes mellitus. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) CZ (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
